Author: Thuc Huynh, MD
Last week, Epocrates went public on the Nasdaq stock exchange. Originally, the company had announced it's starting price to be $16.00 per share. However, the company surprised us all with a strong opening of $20.00 per share.
Now at the end of the week, the EPOC ticker last traded at $26.51. Fantastic. Epocrates has been a leader in mobile drug information since 1998. Over 13 years later and multiple attempts at going public, they have finally succeeded.
If you haven't purchased any shares yet, you should strongly consider doing so. I suspect the stock will continue to grow with the HIMSS conference coming up.
Several months ago, Epocrates had the med-tech world buzzing with news about building an Epocrates EMR. Well, when I was at CES, I stopped by the Epocrates booth and asked them point blank, "When is your EMR coming out?" The representative said, "Soon. All good things come in time."
In June 2009, Epocrates acquired parts of the iChart EMR, the first mobile electronic record. With that acquisition came a great addition to the Epocrates team, Dr. Thomas Giannulli, a physician trained in Internal Medicine and biomedical engineering.
Will this year's HIMSS conference reveal the long awaited Epocrates EMR? Let's hope so.
Dr. Thuc Huynh is CEO of ScrubdIN, a startup company that aims to help health professionals choose their next medical app. Her main interest lies around how medicine can play a role with web 2.0 and social media. Dr. Huynh is currently Chief Resident at her Family Medicine Residency in Rapid City, SD and received her B.S. and M.D. at the Medical University of the Americas.